These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17402160)

  • 1. Parkinson's drugs linked to heart valve trouble.
    Harv Heart Lett; 2007 Apr; 17(8):7. PubMed ID: 17402160
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs and valvular heart disease.
    Roth BL
    N Engl J Med; 2007 Jan; 356(1):6-9. PubMed ID: 17202450
    [No Abstract]   [Full Text] [Related]  

  • 3. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
    Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitral heart disease due to cabergoline.
    Martin M; Iglesias-Cubero G; Diaz Molina B; Moris De la Tassa C
    Int J Cardiol; 2007 Jan; 114(1):e7-8. PubMed ID: 17052783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

  • 12. Valvular health disease with pergolide.
    Prescrire Int; 2003 Dec; 12(68):225. PubMed ID: 14986695
    [No Abstract]   [Full Text] [Related]  

  • 13. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
    Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
    Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
    J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
    Corvol JC; Schüpbach M; Bonnet AM;
    Rev Neurol (Paris); 2005 Jul; 161(6-7):637-43. PubMed ID: 16141947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.